Literature DB >> 16614352

Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease.

Jerry M Wright1, Christian A Merlo, Jeffrey B Reynolds, Pamela L Zeitlin, Joe G N Garcia, William B Guggino, Michael P Boyle.   

Abstract

Despite having identical cystic fibrosis transmembrane conductance regulator genotypes, individuals with DeltaF508 homozygous cystic fibrosis (CF) demonstrate significant variability in severity of pulmonary disease. This investigation used high-density oligonucleotide microarray analysis of nasal respiratory epithelium to investigate the molecular basis of phenotypic differences in CF by (1) identifying differences in gene expression between DeltaF508 homozygotes in the most severe 20th percentile of lung disease by forced expiratory volume in 1 s and those in the most mild 20th percentile of lung disease and (2) identifying differences in gene expression between DeltaF508 homozygotes and age-matched non-CF control subjects. Microarray results from 23 participants (12 CF, 11 non-CF) met the strict quality control guidelines and were used for final data analysis. A total of 652 of the 11,867 genes identified as present in 75% of the samples were significantly differentially expressed in one of the three disease phenotypes: 30 in non-CF, 53 in mild CF, and 569 in severe CF. An analysis of genes differentially expressed by severity of CF lung disease demonstrated significant upregulation in severe CF of genes involved in protein ubiquination (P < 0.04), mitochondrial oxidoreductase activity (P < 0.01), and lipid metabolism (P < 0.03). Analysis of genes with decreased expression in patients with CF compared with control subjects demonstrated significant downregulation of genes involved in airway defense (P < 0.047) and protein metabolism (P < 0.048). This study suggests that differences in CF lung phenotype are associated with differences in expression of genes involving airway defense, protein ubiquination, and mitochondrial oxidoreductase activity and identifies specific new candidate modifiers of the CF phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614352      PMCID: PMC2643286          DOI: 10.1165/rcmb.2005-0359OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  46 in total

1.  A statherin and calcium enriched layer at the air interface of human parotid saliva.

Authors:  Gordon B Proctor; Sawsan Hamdan; Guy H Carpenter; Peter Wilde
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

Review 2.  Energy transduction by respiratory complex I--an evaluation of current knowledge.

Authors:  J Hirst
Journal:  Biochem Soc Trans       Date:  2005-06       Impact factor: 5.407

3.  Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2.

Authors:  Martha Lappas; Michael Permezel; Gregory E Rice
Journal:  Endocrinology       Date:  2005-05-19       Impact factor: 4.736

4.  Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro.

Authors:  O Tabary; J M Zahm; J Hinnrasky; J P Couetil; P Cornillet; M Guenounou; D Gaillard; E Puchelle; J Jacquot
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes.

Authors:  Yoshinari Tanabe; Takeaki Nishibori; Leon Su; Robert M Arduini; Darren P Baker; Michael David
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

6.  Regulated hydrogen peroxide production by Duox in human airway epithelial cells.

Authors:  Radia Forteza; Matthias Salathe; Françoise Miot; Rosanna Forteza; Gregory E Conner
Journal:  Am J Respir Cell Mol Biol       Date:  2005-01-27       Impact factor: 6.914

7.  Innate antimicrobial activity of nasal secretions.

Authors:  A M Cole; P Dewan; T Ganz
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto.

Authors:  M Corey; F J McLaughlin; M Williams; H Levison
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

9.  Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis.

Authors:  G Döring; F Frank; C Boudier; S Herbert; B Fleischer; G Bellon
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

10.  Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity.

Authors:  F Vasseur; N Helbecque; S Lobbens; V Vasseur-Delannoy; C Dina; K Clément; P Boutin; T Kadowaki; P E Scherer; P Froguel
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

View more
  41 in total

Review 1.  Strategies for identifying modifier genes in cystic fibrosis.

Authors:  Michael P Boyle
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 2.  Redox balance in cystic fibrosis.

Authors:  Assem G Ziady; Jason Hansen
Journal:  Int J Biochem Cell Biol       Date:  2014-03-20       Impact factor: 5.085

Review 3.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

Review 4.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

5.  IFNβ/TNFα synergism induces a non-canonical STAT2/IRF9-dependent pathway triggering a novel DUOX2 NADPH oxidase-mediated airway antiviral response.

Authors:  Karin Fink; Lydie Martin; Esperance Mukawera; Stéfany Chartier; Xavier De Deken; Emmanuelle Brochiero; Françoise Miot; Nathalie Grandvaux
Journal:  Cell Res       Date:  2013-04-02       Impact factor: 25.617

6.  Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.

Authors:  Hiroko Hamai; Fannie Keyserman; Lynne M Quittell; Tilla S Worgall
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

7.  Variants in FAM13A are associated with chronic obstructive pulmonary disease.

Authors:  Michael H Cho; Nadia Boutaoui; Barbara J Klanderman; Jody S Sylvia; John P Ziniti; Craig P Hersh; Dawn L DeMeo; Gary M Hunninghake; Augusto A Litonjua; David Sparrow; Christoph Lange; Sungho Won; James R Murphy; Terri H Beaty; Elizabeth A Regan; Barry J Make; John E Hokanson; James D Crapo; Xiangyang Kong; Wayne H Anderson; Ruth Tal-Singer; David A Lomas; Per Bakke; Amund Gulsvik; Sreekumar G Pillai; Edwin K Silverman
Journal:  Nat Genet       Date:  2010-02-21       Impact factor: 38.330

8.  Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.

Authors:  Deepika Polineni; Hong Dang; Paul J Gallins; Lisa C Jones; Rhonda G Pace; Jaclyn R Stonebraker; Leah A Commander; Jeanne E Krenicky; Yi-Hui Zhou; Harriet Corvol; Garry R Cutting; Mitchell L Drumm; Lisa J Strug; Michael P Boyle; Peter R Durie; James F Chmiel; Fei Zou; Fred A Wright; Wanda K O'Neal; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

Review 9.  NADPH oxidases in lung biology and pathology: host defense enzymes, and more.

Authors:  Albert van der Vliet
Journal:  Free Radic Biol Med       Date:  2007-12-05       Impact factor: 7.376

10.  GEOGLE: context mining tool for the correlation between gene expression and the phenotypic distinction.

Authors:  Yao Yu; Kang Tu; Siyuan Zheng; Yun Li; Guohui Ding; Jie Ping; Pei Hao; Yixue Li
Journal:  BMC Bioinformatics       Date:  2009-08-25       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.